An Effective Non-Steroid Atopic Dermatitis Ointment
Anacor Pharmaceuticals (ANAC) Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis
Crisaborole is a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.
In both Phase 3 studies, crisaborole achieved statistically significant results on all primary and secondary endpoints and demonstrated a safety profile consistent with previous studies.
Anacor expects to submit a New Drug Application for crisaborole to the FDA in the first half of 2016.
Anacor hosted a conference call Today at 7:30 a.m. ET to Discuss the Results
To Read about Clinical Trials of Crisaborole Click HERE
Prohost Comments
The successful outcome of Crisaborole ointment stirred investor’s enthusiasm to a degree that boosted the stock price up from around $84 to over $131. Profit takers are taking profit, but their number must have be inferior to the number of new buyers, or accumulators of the stock. Today in premarket and early market ANAC was trading around $127 down around $5 from yesterday closing. Now, at 12.04 PM the stock loss is around $2.5 only after yesterday’s huge rally.
The question is: Does this ointment deserve all this expressed enthusiasm?
To know the answer, investors have to know about Atopic dermatitis. This disease presents as a chronic rash characterized by inflammation and severe itching. Lesions of atopic dermatitis are red, elevated and oozing patches. The impact is harsh, especially for children.
The current treatments revolve around steroids (cortisone ointments and creams), which are somewhat effective, but have many side effects. The local side effects include skin thinning, acne and stretch marks. The systemic side effects include HPA axis suppression and chronic endocrine anomalies, including diabetes and other numerous complications.
That’s why a non-steroidal effective ointment such as Crisaborole is a necessity.
The Revenues could be in the billions of dollars considering the fact that the skin disease affects millions of children. The disease can persist and continue into adulthood. It is estimated the number of people with atopic dermatitis is around 18 to 25 million people in the United States alone, 80% to 90% of them have mild or moderate disease.
One cannot talk about Anacor Pharmaceuticals without referring to its BORON chemistry Platform. It is an interesting story that tells a lot about the firm, its pipeline and its capability. To learn about it click HERE
We loved the news.
Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our ‘opinions’ and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal
Anacor Pharmaceuticals Ointment for Atopic Dermatitis Passes the Tests. Why Is This Great News?
An Effective Non-Steroid Atopic Dermatitis Ointment
Anacor Pharmaceuticals (ANAC) Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis
Crisaborole is a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.
In both Phase 3 studies, crisaborole achieved statistically significant results on all primary and secondary endpoints and demonstrated a safety profile consistent with previous studies.
Anacor expects to submit a New Drug Application for crisaborole to the FDA in the first half of 2016.
Anacor hosted a conference call Today at 7:30 a.m. ET to Discuss the Results
To Read about Clinical Trials of Crisaborole Click HERE
Prohost Comments
The successful outcome of Crisaborole ointment stirred investor’s enthusiasm to a degree that boosted the stock price up from around $84 to over $131. Profit takers are taking profit, but their number must have be inferior to the number of new buyers, or accumulators of the stock. Today in premarket and early market ANAC was trading around $127 down around $5 from yesterday closing. Now, at 12.04 PM the stock loss is around $2.5 only after yesterday’s huge rally.
The question is: Does this ointment deserve all this expressed enthusiasm?
To know the answer, investors have to know about Atopic dermatitis. This disease presents as a chronic rash characterized by inflammation and severe itching. Lesions of atopic dermatitis are red, elevated and oozing patches. The impact is harsh, especially for children.
The current treatments revolve around steroids (cortisone ointments and creams), which are somewhat effective, but have many side effects. The local side effects include skin thinning, acne and stretch marks. The systemic side effects include HPA axis suppression and chronic endocrine anomalies, including diabetes and other numerous complications.
That’s why a non-steroidal effective ointment such as Crisaborole is a necessity.
The Revenues could be in the billions of dollars considering the fact that the skin disease affects millions of children. The disease can persist and continue into adulthood. It is estimated the number of people with atopic dermatitis is around 18 to 25 million people in the United States alone, 80% to 90% of them have mild or moderate disease.
One cannot talk about Anacor Pharmaceuticals without referring to its BORON chemistry Platform. It is an interesting story that tells a lot about the firm, its pipeline and its capability. To learn about it click HERE
We loved the news.
Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our ‘opinions’ and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal
Other Articles